PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease Reportspseudomonas infections
MeSH D011552 - pseudomonas infections
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D016905:Gram-negative bacterial infections
$
Success rate
D011552: 
Pseudomonas infections
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Abbott BiotherapeuticsAmikacin Amikacin  1994-11-30   
AbbVieAvibactam, Ceftazidime Avycaz 2026-01-07 2015-02-25   
Alcon ResearchDexamethasone, Neomycin, Polymyxin b Neomycin Polymyxin B Sulfates Dexamethasone  1986-11-17   
Neomycin, Polymyxin b Statrol  1984-11-30   
Tobramycin Tobramycin  1994-05-25   
Alembic PharmaceuticalsTobramycin Tobramycin  2019-04-19   
ALK-AbellóCiprofloxacin Otiprio 2029-04-21 2015-12-10   
Alkem LaboratoriesTobramycin Tobramycin  2021-04-01   
AllerganPrednisolone, Neomycin, Polymyxin b Poly-pred  1982-01-01   
Ciprofloxacin Ciprofloxacin  2005-01-21   
Neomycin, Polymyxin b Neomycin Polymyxin B  1986-04-08   
Gramicidin, Neomycin, Polymyxin b Neomycin Polymyxin B Sulfates Gramicidin  1987-06-11   
Hydrocortisone, Neomycin, Polymyxin b Otocort  1982-01-01   
Tobramycin Tobramycin  1989-08-09   
Altaire PharmaceuticalsCiprofloxacin Ciprofloxacin  2018-05-03   
AltanaHydrocortisone, Bacitracin, Neomycin, Polymyxin b Bacitracin-neomycin-polymyxin W/ Hydrocortisone  1982-01-01   
1
2
3
4
5
6
...
13
>
Clinical Trials
Historical Success Rate
Phase 1
0%
0/6
Phase 2
0%
0/1
Phase 3
97%
31/32
Approved: 27Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
AbbVie
1
2
3
4
5
6
...
9
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use